Excelimmune Raises $12 Million to Advance Infectious Disease Programs and Expand its HRPA Platform

Excelimmune Raises $12 Million to Advance Infectious Disease Programs and Expand its HRPA Platform
December 20th, 2011

Woburn, Mass. - December 20, 2011 - Excelimmune, Inc. today announced that the company has raised $12 million from a private investor. Proceeds will be used by Excelimmune to develop its infectious disease programs, including Staphguard, a human recombinant polyclonal antibody (HRPA) candidate against methicillin-resistant Staphylococcus aureus (MRSA), and to expand its discovery programs to new disease targets beyond infectious diseases through its antibody screening technology.

"Novel treatments in nocosomial infections that can overcome treatment challenges such as resistance are urgently needed, and the continued financial support will enable us to advance our programs toward clinical trials," said Quinton Zondervan, Chief Executive Officer or Excelimmune. "We believe HRPAs will provide a safer and more effective treatment option for nocosomial infectious compared to conventional anti-infective drugs. Beyond infectious diseases, HRPAs have broad potential across multiple therapeutic areas, for which we are pursuing partnerships. We are also expanding our personnel and pipeline to further exploit our technology's potential."

About Human Recombinant Polyclonal Antibodies
Human recombinant polyclonal antibodies are mixed populations of therapeutic antibodies that bind to multiple regions (epitopes) on a specific antigen or to multiple antigens (of bacteria, viruses and other microorganisms), in contrast to monoclonal antibodies, which only bind to one specific epitope. By binding to multiple regions, the polyclonal antibodies allow the body to fight off illness more readily. The antibodies are cloned from naturally occurring human antibodies in a laboratory and are then manufactured for human medical use.
About Excelimmune
Excelimmune, Inc. is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. Excelimmune's antibody therapies harness the diversity and effectiveness of the human body's adaptive immune system. The company is initially focusing on the treatment of infections caused by Staphylococcus aureus, including the drug resistant superbug, MRSA. This next generation technology is also believed to be applicable in the treatment of other pathogenic bacteria and viruses, disease causing proteins, and cancer. Excelimmune, founded in 2006, is a private company located in Woburn, Mass. www.excelimmune.com.
Contacts
Excelimmune:
Quinton Zondervan, 617-497-4303 x10 (NO SOLICITING)
CEO

Media:
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
[email protected]

 

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.